Myriad Genetics Completes Enrollment in U.S. Phase 3 Clinical Trial of Flurizan for Alzheimer's Disease:

Myriad Genetics Completes Enrollment in U.S. Phase 3 Clinical Trial of Flurizan for Alzheimer's Disease: "Myriad Genetics, Inc. announced today that it has completed enrollment in its U.S. Phase 3 clinical trial of Flurizan™ for patients with Alzheimer's disease. "